ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages AST SpaceMobile, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ASTS
April 21, 2024 12:11 ET
|
The Rosen Law Firm PA
NEW YORK, April 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of AST...
DEADLINE ALERT for VFS, QDEL, and ASTS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
April 19, 2024 12:09 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, April 19, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
SHAREHOLDER ALERT: AST SpaceMobile Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
April 19, 2024 07:50 ET
|
Block & Leviton LLP
BOSTON, April 19, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against AST SpaceMobile, Inc. (NASDAQ: ASTS) for securities law violations. Investors who purchased shares and have...
SPACEMOBILE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AST SpaceMobile, Inc. and Encourages Investors to Contact the Firm
April 18, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against AST...
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
June 07, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
April 24, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
October 13, 2022 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and...
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 17, 2021 09:25 ET
|
Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
Applied Impact Robotics, Developers of an Automated Inspection Solution for Capital Intensive Infrastructure, Appoints Jim Nyquist to its Board of Directors as an Independent Director
July 28, 2021 08:00 ET
|
Applied Impact Robotics
Sterling, Virginia, July 28, 2021 (GLOBE NEWSWIRE) -- Applied Impact Robotics (AIR), developers of a solution for the in-service inspection and maintenance of Aboveground Storage Tanks (ASTs),...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
May 04, 2021 16:30 ET
|
Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...